Summary curves for patients transplanted for chronic myeloid leukaemia salvaged by a donor lymphocyte infusion: the current leukaemia-free survival curve.
A significant number of patients who relapse after allogeneic stem cell transplantation (SCT) for chronic myeloid leukaemia (CML) will achieve sustained molecular remissions after treatment with donor lymphocyte infusions (DLI) from the original stem cell donor. Leukaemia-free survival, defined as survival without evidence of relapse at any time after transplant does not account for patients who are successfully treated with DLI. To summarize adequately the response to treatment, a new summary probability, called the current leukaemia-free survival (CLFS), is proposed. This quantity is defined as the probability that a patient is alive and in remission at a given time after transplant. We discuss two statistical methods for estimating CLFS. The first is based on a multistate modelling approach. The second is based on an estimate constructed by looking at appropriate differences between Kaplan-Meier estimates. We compare these estimates using data on 189 consecutive patients who underwent SCT over a 7-year period.
Klein
J P
JP
The Division of Biostatistics, Medical College of Wisconsin, Milwaukee, WI, USA. klein@mcw.edu
Keiding
N
N
Shu
Y
Y
Szydlo
R M
RM
Goldman
J M
JM
D019264:Adoptive Transfer / Q000379:methods*; D003131:Combined Modality Therapy; D018380:Hematopoietic Stem Cell Transplantation; D006801:Humans; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000628:therapy*; D015233:Models, Statistical; D012008:Recurrence; D015996:Survival Rate